Medof M E, Oger J J, Antel J P, Prince G M
J Clin Lab Immunol. 1982 Feb;7(2):93-103.
Blood cells from patients with systemic lupus erythematosus (SLE) and from healthy control subjects were studied for their ability to bind exogenous immune complexes. Cells were mixed with experimental complexes (prepared from 125I-radiolabeled bovine serum albumin [BSA] and guinea pig antiserum to BSA) after incubation of the complexes with autologous serum in variable proportions. Unfractionated blood cells from SLE patients bound fewer added complexes (mean +/- SD = 39.8% +/- 12.9%) than cells from normal controls (mean +/- SD = 63.6% +/- 9.5%) (p less than 0.001); as much as 128-fold (mean = 23-fold) higher (p less than 0.01) proportions of serum to complex were required to optimize the lower binding. When SLE blood cells were mixed with complexes preincubated with normal sera instead of autologous SLE sera, SLE cells bound increased amounts of added complexes, and binding was optimal at the same lower proportions of serum to complex as for normal cells. When normal cells were mixed with complexes preincubated with compatible SLE sera in place of endogenous normal sera, binding to normal cells decreased to SLE levels, and the same higher proportions of serum to complex were required to optimize the lower binding as for the SLE cells. Similar results were obtained when binding to purified mononuclear cell preparations from SLE patients and controls was studied. When comparative studies were performed at high complex-to-cell ratios with complexes prepared using normal sera, SLE cells bound fewer complexes per cell than normal cells. These results indicate that although abnormalities in SLE cells are demonstrable, the major factor accounting for aberrant interaction between immune complexes and SLE cells resides in alterations in SLE sera.
对系统性红斑狼疮(SLE)患者及健康对照者的血细胞进行研究,以观察其结合外源性免疫复合物的能力。将复合物与自体血清按不同比例孵育后,再与实验复合物(由125I放射性标记的牛血清白蛋白[BSA]和豚鼠抗BSA血清制备而成)混合。SLE患者的未分级血细胞结合的添加复合物比正常对照者的细胞少(均值±标准差 = 39.8%±12.9%),而正常对照者的细胞为(均值±标准差 = 63.6%±9.5%)(p<0.001);需要高达128倍(均值 = 23倍)(p<0.01)的血清与复合物比例才能优化较低的结合。当SLE血细胞与用正常血清而非自体SLE血清预孵育的复合物混合时,SLE细胞结合的添加复合物量增加,且在与正常细胞相同的较低血清与复合物比例下结合最佳。当正常细胞与用相容的SLE血清而非内源性正常血清预孵育的复合物混合时,正常细胞的结合降至SLE水平,且与SLE细胞一样,需要相同较高的血清与复合物比例来优化较低的结合。研究SLE患者和对照者纯化的单核细胞制剂的结合时也得到了类似结果。当使用正常血清制备的复合物在高复合物与细胞比例下进行比较研究时,每个SLE细胞结合的复合物比正常细胞少。这些结果表明,尽管SLE细胞存在异常,但免疫复合物与SLE细胞之间异常相互作用的主要因素在于SLE血清的改变。